Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention
Go back to Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention| (NASDAQ: MDCX) | Delayed: 0.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.42 | 52 Week High | $ | |||
| Open | $63.40 | 52 Week Low | $ | |||
| Day High | $0.42 | P/E | N/A | |||
| Day Low | $0.42 | EPS | $ | |||
| Volume | 34,093 | |||||
